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CalsequestrinThis review focuses on muscle disorders and diseases caused by defects in the Ca2+ release channels of the
sarcoplasmic reticulum, the ryanodine receptors, and in the luminal, low afﬁnity, high capacity Ca2+-binding
proteins, calsequestrins. It provides a time line over the past half century of the highlights of research on
malignant hyperthermia (MH), central core disease (CCD) and catecholaminergic polymorphic ventricular
tachycardia (CPVT), that resulted in the identiﬁcation of the ryanodine receptor (RYR), calsequestrin (CASQ)
and dihydropyridine receptor (CACNA1S) genes as sites of disease-causing mutations. This is followed by a
description of approaches to functional analysis of the effects of disease-causing mutations on protein
function, focusing on studies of how mutations affect spontaneous (store overload-induced) Ca2+-release
from the sarcoplasmic reticulum, the underlying cause of MH and CPVT. Subsequent sections describe results
obtained by analysis of knockin mouse lines carrying MH- and CCD-causing mutations, including a Casq1
knockout. The review concludes with the presentation of two mechanistic models. The ﬁrst shows how
dysregulation of Ca2+ homeostasis can lead to muscle diseases involving both RyR and Casq proteins. The
second describes a theory of central core formation wherein non-uniformity of Ca2+ release, resulting in non-
uniformity of muscle contraction, is presented as an intrinsic property of the speciﬁc tertiary structure of
mutant heterotetrameric ryanodine receptors and as the underlying cause of core formation in skeletal
muscle. This article is part of a Special Issue entitled: 11th European Symposium on Calcium.ropean Symposium on Calcium.
+1 416 978 8528.
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Dr.WitoldDrabikowskiwas apioneer in the investigationof proteins
of the skeletalmuscle I-ﬁlament,whomademany early contributions to
our understanding of actin polymerization, its interaction with
tropomyosin and the Ca2+ binding properties of troponin. In about
1970, he became interested in proteins of the sarcoplasmic reticulum
and trained a series of students in that area. Tomygood fortune, he then
sentDrs. Elzbieta Zubrzycka,MarekMichalak and BozenaKorczak tomy
laboratory for postdoctoral work. Each of these talented, well-trained
individualsmade unique and lasting contributionswhile working inmy
lab and in their later studies. For example, Elzbieta advancedmuscle cell
culture and cell biology in our lab [1] and later, in Dr. RonWorton's lab,
she made antibodies to dystrophin, which, in mutant form, causes
Duchenne muscular dystrophy. With Drs. Worton and George Karpati,
she was the ﬁrst to describe the association of dystrophin with
sarcolemmal vesicles [2,3]. Marek has deﬁned the many interesting
properties of the ER luminal chaperone protein, calreticulin [4,5].Bozena was deeply involved in the ﬁrst cloning of SERCA cDNA and
ATP2A genomic DNA [6,7].
As wemeet to celebrate the life of Dr.Witold Drabikowski, we look
back to the discoveries that were being made during his lifetime and
think about progress that has been made since then in the ﬁelds that
were of interest to him. The developments that we will review have
taken place since about 1960. They concern muscle disorders and
diseases caused jointly by defects in the Ca2+ release channels of the
sarcoplasmic reticulum, commonly referred to as ryanodine receptors
(RyR) – the skeletal muscle RyR1 isoform encoded by the RYR1 gene
on human chromosome 19q13.1, and the cardiac RyR2 isoform
encoded by the RYR2 gene on human chromosome 1q42.1–43 – and
by defects in the luminal, low afﬁnity, high capacity, Ca2+ binding/
buffering protein referred to as calsequestrin (Casq)— skeletal muscle
Casq1, encoded by the CASQ1 gene on human chromosome 1q21 and
cardiac Casq2, encoded by CASQ2 on human chromosome 1p13.3–
p11. In early sections, we will provide a time line over the past half
century of the highlights of research on malignant hyperthermia
(MH), central core disease (CCD) and other core myopathies and
catecholaminergic polymorphic ventricular tachycardia (CPVT) and,
in the concluding sections, we will offer unifying theories for the
etiology and the pathogenesis of all of these muscle disorders and
diseases.
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2.1. Malignant hyperthermia
The year 2010 marks the 50th anniversary of Dr. Michael
Denborough's groundbreaking description of an episode of malignant
hyperthermia (MH) in a patient with a family history of anesthetic-
related deaths [8]. Forewarned, Dr. Denborough recognized the initial
stages of the MH episode and was able to intervene successfully,
saving the patient from certain death from this dreaded side effect of
surgery under anesthesia. Because of his insights and his personal
efforts to publicize the disorder [9,10], MH would, henceforth, be
viewed as an inherited disorder that could be studied, understood and
prevented.
MH (MH; MIM# 145600) is a subclinical, autosomal dominant
pharmacogenetic disorder of skeletal muscle caused by defective
intracellular Ca2+ homeostasis and presenting with a fulminant and
potentially lethal hypermetabolic reaction to inhalational anesthetics
and the depolarizing muscle relaxant, succinylcholine [11,12]. The
incidence of an MH episode is 1 in 60,000 adults and 1 in 15,000
children and adolescents undergoing anesthesia [13,14]. However,
recent estimates are that the actual proportion of individuals, carrying
the MH trait, is as high as 1 in 2000 [15]. Genetic testing has shown
that about 70% of MH patients have defects in the RYR1 gene (MIM
180 901) [12,16,17], while a few MH patients have mutations in the
CACNA1S gene (MIM 114 208) [15,18–22] encoding the α1-subunit of
the skeletal muscle voltage-dependent L-type Ca2+ channel (Cav1.1),
located in the transverse tubular membrane.
An anesthetic-induced MH episode is manifested as a rapid and
uncontrolled rise in myoplasmic Ca2+, leading to sustained skeletal
muscle rigidity and hypermetabolism and accompanied by a critical
drop in ATP levels, acidosis, hypercapnia, tachycardia and an
abnormal rise in body temperature [16]. Many of these signs and
symptoms are monitored routinely during anesthesia in most modern
hospitals and a rapid change in any of these parameters calls for
immediate cessation of anesthesia and administration of dantrolene, a
potent antidote to anesthetic-induced MH [23–25]. Such precautions
reduced fatality fromMH from over 80% to less than 10% in the 1990s,
but recent surveys on the occurrence of MH in North American clinical
institutions show alarming statistics — a rise in MH-associated
morbidity to 35% [24] and a rise in MH mortality to 14% [26] during
the ﬁrst decade of the 21st century, presumably because of the use of
MH-triggering anesthetics outside of conventional hospital settings
[27]. This highlights the need for more comprehensive genetic testing
that would alert physicians to the MH susceptibility (MHS) status of
patients and the need for a better understanding of the etiology and
pathophysiology of the underlying MH defect.
2.2. Central core disease (CCD) and related congenital myopathies
Central core disease (CCD, OMIM #117,000) was ﬁrst described in
1956 as a rare, non-progressive congenital myopathy, characterized
by hypotonia and proximal muscle weakness and presenting with
well-delineated areas of myoﬁbrillar disorganization (cores) within
myoﬁbers [28]. Additional variable clinical features include pes cavus,
kyphoscoliosis, foot deformities, congenital hip dislocation and joint
contracture [29]. Although clinical signs of CCD may be severe, up to
40% of individuals demonstrating central cores may be asymptomatic
[30,31] and lead lives requiring considerable physical exertion.
In 1960, Dubowitz and Pearse [32] described histochemical studies
showing that “core” regions within the myoﬁber of CCD patients did
not react with stains for phosphorylase and oxidative enzyme activity.
The diagnosis of CCD has since been made on the basis of skeletal
muscle weakness and the lack of oxidative enzyme activity in the
central regions of skeletal myoﬁbers. In 1961, Engel et al. [33] showed
that the cores lacked mitochondria and a well-organized sarcotubularsystem and that myoﬁbrillar organization was disrupted. Electron
microscopic analysis of the cores showed disintegration of the
contractile apparatus, ranging from blurring and streaming of the Z
lines to total loss of myoﬁbrillar structure [34,35]. The sarcoplasmic
reticulum and transverse tubular systems were increased in content
and were, in general, less well structured. Mitochondria were
depleted in the cores, but may have been enriched around the
surfaces of the cores, while retaining normal structural organization.
In 1973, Denborough et al. [36] showed a close association of CCD
with MH susceptibility. This association had important genetic
consequences because it prompted studies of the genetic basis of
MH to be carried out in parallel with studies of the genetic basis of
CCD. Some mutations in the RYR1 gene have been associated with
both MHS and slowly progressive skeletal muscle weakness and cores
in some, but not necessarily all, MHS members within a family, giving
rise to the diagnosis of MH/CCD [17,37]. Some investigators [38–41]
have argued that an MH/CCD diagnosis for cases of MH that present
with cores may not be valid in the absence of muscle weakness.
Indeed, detailed histopathological examinations show that MH is an
asymptomatic myopathy and the presence of cores in myoﬁbers does
not necessarily mean CCD, since the development of cores can be non-
speciﬁc and is observed in many cases of muscle injury unrelated to
CCD [33,42–44]. Thus it has been suggested that MH cases presenting
with cores in the absence of muscle weakness might be more
appropriately referred to as MH with cores and not MH/CCD [38,40].
Other RyR1-related myopathies are multiminicore disease (MmD)
[45], MmD with external ophthalmoplegia (OMIM #255320) [46],
congenital myopathy with cores and rods [47,48], central nuclear
myopathy [49], neuromuscular diseasewith uniform type 1 ﬁbers [50]
and congenital ﬁber type disproportion [51]. For all of these disorders,
Ca2+ dysregulation is likely to be a primary cause and a common
etiology is possible.2.3. Catecholaminergic polymorphic ventricular tachycardia (CPVT)
CPVT is a congenital arrhythmogenic cardiac disorder that was ﬁrst
described in 1978 [52], with a follow-up report in 1995 [53]. It
manifests in apparently healthy juveniles or young adults as syncopal
events (blackouts) or, occasionally, with sudden cardiac death as the
ﬁrst clinical indicator of the disease. As with an MH reaction, an
arrhythmogenic episode can be fatal if undiagnosed or untreated, but
can be managed if diagnosed early. Arrhythmogenic events are
usually triggered in response to intensive exercise or emotional stress
[54–56]. Estimates of the contribution of CPVT to the incidence of
sudden death range from 15% to 30%.
The diagnosis of CPVT is difﬁcult because cardiac evaluation, even
when supplemented with echocardiograms and electrocardiograms,
often fails to detect any defect. CPVT is suspected when exercise stress
tests show isolated premature beats at the beginning of exercise, with
a progressive worsening of the complexity of ventricular arrhythmias
in response to an increasedworkload [52,57]. Bidirectional ventricular
tachycardia (VT), which is characterized by a 180° beat-to-beat
rotation of the axis of the QRS complexes on the frontal plane, is
considered the diagnostic marker of CPVT, but not all patients
manifest this form of arrhythmia.
Investigations of the genetic basis of CPVT [57–60] showed that it
was caused, in part, by dominant mutations in RYR2, the cardiac
ryanodine receptor (RyR2) gene [57], and, in part, by recessive
mutations in CASQ2 [60] that cause loss, truncation and/or misfolding
of cardiac calsequestrin (Casq 2) [61–65]. The incidence of causal RYR2
mutations is at least an order of magnitude higher than the incidence
of causal CASQ2mutations. The fact that the CPVT phenotype is almost
identical, regardless of whether the causal gene is RYR2 or CASQ2, in
both humans and in mice [61–65], suggests that the causal mechanism
is the same.
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episode occurs in the absence of structural alterations to the heart and
requires the presence of both a causal mutation and stressful
conditions that induce β-adrenergic stimulation. Indeed, CPVT
responds to β-blockers [66,67]. This is highly analogous to MH in
which triggering of an MH reaction, in the absence of any structural
alteration of the skeletal muscle, requires the presence of both a
causal mutation and either a triggering anesthetic or, in the case of
pigs, stressful conditions.
3. A time-line of major advances in MH, CCD and CPVT research
3.1. Ca2+ regulation
Early investigations of MH [8,9,68] and CCD [28,69] coincided with
other relevant advances in muscle research. The most important of
these was the rediscovery, after a hiatus of knowledge lasting several
decades, that skeletal muscle contraction requires Ca2+ [70–75]. A
beautifully reasoned review from this time by Dr. Setsuro Ebashi [76]
describes robust experimental evidence showing that Ca2+ regulation
of skeletal muscle contraction occurs within a complex of actin,
myosin, tropomyosin (Tm) and the troponin (Tn) complex, a topic
that was of great interest to Dr. Witold Drabikowski. Binding of Ca2+
with high afﬁnity to the TnC component of the Tn complex initiates
complex conformational changes in both Tn and Tm that shift the
location of the TN–Tm complex, permitting contractile interactions
between actin andmyosin that were precluded by the structure of the
Tn–TM–actin complex in the absence of Ca2+ [77]. Thus it was
apparent to MH researchers that the contracture induced in an MH
reaction would, inevitably, require elevation of regulatory Ca2+ in
those skeletal muscles involved in an MH episode.
3.2. Metabolic regulation
In 1968, Dr. Edwin Krebs' group discovered a cAMP-dependent
protein kinase (PKA) that phosphorylates and activates phosphory-
lase kinase [78]. In 1971, the same group demonstrated that activation
of phosphorylase kinase to phosphorylate and activate phosphorylase
also requires Ca2+ (one subunit of phosphorylase kinase is the Ca2+
binding and regulatory protein, calmodulin) [79]. These discoveries
led to understanding of the key, coordinated roles of cAMP, PKA and
Ca2+ in adrenergic signaling pathways in muscle [80] and, since
glycogenolysis, catalyzed by activated phosphorylase, is the ﬁrst step
in glycolysis, MH researchers immediately understood that adrenergic
pathways must be involved in the elevation of anaerobic metabolism
(hypermetabolism) and the increase in blood glucose that were
observed during an MH episode.
3.3. Pig model of MH
By the mid-1960s, Hall [81] and Harrison [82] recognized that
individual animals in certain lines of pigs were sensitive to volatile
anesthetics. Homozygous MH pigs, when subjected to a short,
controlled exposure to halothane (the halothane challenge test),
developed symptoms characteristic of an MH episode seen in
heterozygous MHS humans exposed to halothane, often in the
presence of succinylcholine [83]. Fortuitously, breeders selecting for
pigs with large hams and lean muscle mass had embedded a single
autosomal HAL gene (the MH gene) into an exceptionally useful
animal model for MH, since pigs and humans have a comparable body
size [16]. In addition to the apparent differences in MH inheritance –
recessive in pigs, but dominant in humans – there were other
apparent differences between MH presentation in pigs and in affected
humans. For example, anMH episode is frequently triggered in pigs by
exercise, overheating, mating or by emotional stress induced during
shipping to the slaughterhouse, so that, in those days, 1–2% of pigsdied before reaching market. It was thus clear that an adrenergic
trigger was driving what was known as the porcine stress syndrome
(PSS) [83,84]. Moreover, theMH episode did not cease after slaughter,
but continued in cuts of meat on the packaging line, giving rise to pale,
soft, exudative (PSE) pork [85,86].
3.4. Metabolic and ionic changes in MH
In 1970, Dr. Mervyn Berman examined a range of changes in
metabolism and ionic composition in pigs following exposure to
halothane [87]. He noted a shift of water into the intracellular space,
so that serum Na+ and total protein concentration were elevated,
together with a shift of Ca2+ andMg2+ into the extracellular space. He
also observed: release of PO43− into the plasma; an elevation in blood
glucose; an uncompensated metabolic acidosis, resulting entirely
from a rise in plasma lactate; lowered arterial pO2 and elevated pCO2.
These biochemical changes preceded temperature elevation and were
not associated with heat injury. The rise in blood glucose and excess
lactate production resulted from uncontrolled glycogenolysis. Anaer-
obic sources of heat included glycolysis, the neutralization of lactic
acid and the hydrolysis of high-energy phosphate esters (e.g. ATP).
Fever was not caused by oxidative mechanisms or by the uncoupling
of oxidative phosphorylation. The observed rise in muscle protein
concentrations in the blood – chieﬂy myoglobin and creatine kinase –
indicated muscle ﬁber damage. The release of Ca2+ from myoﬁbers
supported the role of abnormal Ca2+ homeostasis in MH, but it was
the elevation of blood K+ levels from 4 mM to 6–7 mM that was most
critical, since these concentrations of K+ in the serum cause cardiac
arrest in humans. Hyperthermia is a relatively late sign — it develops
10–15 min after the onset of the reaction [16,83,87].
3.5. Primary site of the MH reaction
In addition to the question of whether the MH defect lay in
regulatory Ca2+ levels, it became important to early MH researchers
to know whether the site of the defect was within organelles inside
myoﬁbers or in electrically excitable membranes of the nerves or the
sarcolemma. In the early 1960s, Ebashi [71,73,74] and Hasselbach
[88,89] established that isolated sarcoplasmic reticulum (SR) vesicles
can take up Ca2+ in substantial amounts, demonstrating that the
“Marsh relaxing factor” [90] is a preparation of SR vesicles. At this
time, caffeine was found to induce skeletal muscle contracture and to
release Ca2+ as a result of the direct action of the drug on the
sarcoplasmic reticulum [91]. Thus, from these early times, the
sarcoplasmic reticulum was recognized as the probable site of the
MH defect and moreover, caffeine became the ﬁrst important drug for
investigation of the primary site of the MH reaction [92].
In equally important studies from this time, Dr. Makoto Endo
showed that Ca2+ release from the skeletal muscle SR is regulated by a
high afﬁnity Ca2+ sensor site on the cytosolic surface of the Ca2+
release channel so that a rise in cytosolic Ca2+ to 1 μMor higherwould
trigger further Ca2+ release in a process that he termed Ca2+-induced
Ca2+ release (CICR) [93]. Dr. Alexandre Fabiato later demonstrated
that excitation–contraction (EC) coupling in cardiac muscle ismediated
by CICR [94].
3.6. In vitro diagnostic tests for MH
The ﬁrst to take advantage of the knowledge that caffeinemight be
a useful tool in MH research was the team of Dr. Werner Kalow, often
described as the “father of pharmacogenetics”, and Dr. Beverley Britt,
an anesthesiologist devoted to unraveling the biochemical and
genetic bases for MH and to the development of preoperative
diagnosis of MHS. In an ingenious synthesis of talents and ideas,
they isolated muscle ﬁbers from MHS and normal patients and
measured the development of contracture of ﬁbers, mounted on a
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tension developed inMHS ﬁbers at lower caffeine concentrations than
normal. Shortly thereafter, Richard Ellis established, using the Kalow–
Britt approach, that MHS ﬁbers are also hypersensitive to halothane
[96]. Thus the North American caffeine–halothane contracture test
(CHCT) [97] and the European in vitro contracture test (IVCT) [98]
were born. They have proven useful in the preoperative testing of
thousands of potential MHS individuals and, when performed with
rigor, are considered the “gold standard” of MHS status [12]. They are,
however, not perfect, with 97% sensitivity and 78% speciﬁcity for the
CHCT and 99% sensitivity and 94% speciﬁcity for the IVCT [37,99–101].
Conceptually, this work proved that the development of contracture,
seen in whole body studies, can be recapitulated in an isolated ﬁber.
Clearly MHS is a malfunction of skeletal muscle alone.
3.7. Lack of histochemical ﬁndings in MH
Once it was clear that the primary cause of MH resides in skeletal
muscle, it became important to determine whether any structural
defects might be present that could be used in diagnosis, in
understanding of the etiology of MH, or both. Thus a huge effort
was invested in a search for structural abnormalities in muscle
biopsies of MH patients and MHS pigs [102,103]. Initial studies were
of autopsy material or of muscle biopsies from those rare survivors of
an MH episode. In both cases, hypercontracted ﬁbers were often
observed. In MH survivors, individual ﬁber atrophy and necrosis,
together with increased central nucleation, suggestive of myoﬁber
regeneration, were also common ﬁndings [103,104]. However,
abnormalities that could manifest as a pre-existing myopathy were
rare. Samples showed normal ﬁber typing and normally structured
myoﬁbrils, sarcomeres, triads, SR and mitochondria. In some autopsy
material, ﬁbers showed dilation of the SR and swelling or rupture of
mitochondria, but these occasional ﬁndings were believed to be the
consequence of anMH crisis or to represent an artifact known to occur
in highly irritable muscle [103–106].
In MHS pig muscle, carefully collected ante-mortem samples
revealed normal muscle histology and ultrastructure, whereas post-
mortem samples, collected within the ﬁrst 10–12 min after immedi-
ate death by stunning, sometimes showed dramatic myoﬁbrillar
disorganization, hypercontraction and mitochondrial swelling [85].
Britt [107] suggested that the rare cases of mitochondrial swelling
observed in MHS human and pig muscle samples, are caused by
hypoxia, a concomitant feature of an MH episode. Eventually, it
became difﬁcult to promulgate a case for any pre-existing structural
abnormality, especially when muscle biopsies of a growing number of
CHCT or IVCT positive MHS patients, over a range of age groups, and
especially those of MHS children, were found to be morphologically
normal [13,85,102,103,106,108,109].
To put an end to the idea that pre-existing structural abnormalities
occur in MHS muscle, Harrison [110] and Venable [111] made direct
comparisons of porcine muscle biopsies taken immediately before,
during, and just after an MH reaction. They showed repeatedly, using
samples from various muscle groups, that myoﬁbrillar organization in
the muscles of MHS pigs was normal prior to an MH episode, but was
dramatically disrupted within minutes after exposure to an MH-
triggering anesthetic [85,110–113]. In a detailed study by Venable
[111], muscle samples were collected sequentially from pigs, relaxed
under non-triggering anesthesia, with a subsequent switch to graded
levels of 1–3% halothane. Following halothane exposure, the mor-
phologically normalmyoﬁbers from all muscle groupswere converted
into disorganized masses, with areas of intercalated super-contracted
and super-stretched sarcomeres and coagulated contraction clots.
This altered morphology was similar, if not identical, to that of PSE
pork [85], identiﬁed occasionally on the cutting line after slaughter.
In rigorous studies on numerous MHS and MHN human muscle
biopsies, Harriman presented the most convincing proof of theabsence of speciﬁc pathological features in MHS human muscle
prior to anesthetic exposure [102,103]. His methodical analysis of
1400 muscle biopsies from IVCT-tested MHS and control muscle
samples revealed only minor, if any, differences between the samples.
Seventy percent of the MHS muscle samples were seen to be normal
when examined by histochemistry and electron microscopy
[102,103]. He conﬁrmed the results of earlier studies showing that
the most common abnormalities in MHS muscles are slightly
increased ﬁber size variability, an increase in the number of internal
nuclei and the presence of cores in individual ﬁbers. However,
essentially the same abnormalities were observed in control samples,
althoughwith lower frequency. In a later study by Figarella-Branger et
al. [114], involving 165 patients, these alternations were shown to be
as frequent in control muscle samples as in those from MH patients,
strongly indicating that they were non-speciﬁc. More recently, an in-
depth, quantitative, histomorphological analysis of abnormalities in
132 MHS, 65 MHE and 243 MHN muscle biopsies [115] revealed
similar levels of myopathologic abnormalities in muscles from all
three groups. All of these studies led to the conclusion that histo-
pathological examinations cannot aid in the diagnosis of MH and form
the basis for the currently accepted view that MH is an asymptomatic
myopathy.
3.8. Dantrolene as an antidote to MH
A second drug that has proven to be critical, not only to MH
research, but also to MH therapy, is dantrolene sodium. In early work,
Dr. Keith Ellis discovered that dantrolene is a direct acting muscle
relaxant, which blocks the development of an MH episode by
decreasing intracellular Ca2+ concentrations [116–122]. For a recent
review see [25]. The discovery of the suppressant effect of dantrolene
on MH reaction is recognized as one of the most important advances
inMH therapy. The introduction of dantrolene intomedical practice in
1979 as a clinical antidote forMH episodes dramatically decreased the
mortality rate due toMH from about 80% in the 1960s to less than 10%
in the1990s [25]. It is now standard practice in the Western world to
maintain supplies of dantrolene in all hospital operating rooms
(although not necessarily in non-hospital venues). The major
disadvantages of dantrolene are its relatively short shelf life, poor
water solubility, which makes rapid preparation of intravenous
solutions difﬁcult in emergency situations, and the high cost of the
drug. Azumolene, an analogue of dantrolene with 30-fold greater
water solubility, has been shown to be equipotent in preventing
anesthetic-induced MH but, to date, it has not been introduced into
practice [25]. Of interest are recent ﬁndings that dantrolene might
also exert a regulatory action on the cardiac Ca2+ release channel,
RyR2, in failing hearts [123].
Dantrolene has been shown to inhibit the RyR1 Ca2+ release
channel directly and thus to affect the intrinsic mechanism of EC
coupling [124]. It acts by reducing muscle twitch force and by shifting
the sensitivity of contractile activation to higher voltages [25], but the
exact mechanism of its inhibitory action is unknown. Using [3H]
azidodantrolene, a pharmacologically active, photoafﬁnity-labeled
analogue of dantrolene, a dantrolene-binding site within RyR1 was
identiﬁed in the region Leu590–Cys609 [125]. Dantrolene has been
shown to produce a local conformational change within an MH
mutant RyR1, reinforcing the idea that it alters regulatory inter-
domain interactions within the Ca2+ release channel [126]. This
ﬁnding suggests a novel mechanism for dantrolene action as a
stabilizer of an inhibited conformational state of RyR1 [126].
It has been difﬁcult to pinpoint the mechanism of dantrolene
action because, even though it is clear that it diminishes Ca2+ release
channel function in situ, it does not alter the activity of single RyR1
channels or of RyR1 in isolated SR vesicles of varying degrees of purity.
The least complex system in which dantrolene regulates function is in
HEK-293 cells expressing RyR [127]. Thus it appears that only RyR1
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be inhibited by dantrolene. This raises the possibility that dantrolene
acts through an ancillary protein that regulates RyR1 function, but no
such protein has been found and, moreover, dantrolene binds to RyR1.
But what about structural organization within RyR1 arrays as a clue to
their functional inhibition by dantrolene? Dr. Anthony Lai has
analysed the way in which RyR1 tetrameric molecules are organized
under physiological conditions, with subdomain 6 in each subunit
interacting directly with subdomain 6 in an adjacent RyR1 tetramer
[128,129]. He has proposed that each RyR1 tetramer is structurally,
and probably functionally, coupled with 4 other RyR1 tetramers. Is it
then possible that a group of at least 5 functionally connected RyR1
tetramers may be the minimal level of organization required for
inhibition by dantrolene?
3.9. Ryanodine and the identiﬁcation of the Ca2+ release channel
A third drug that facilitated MH research is ryanodine [130]. This
plant alkaloid has the ability to regulate intracellular Ca2+ concentra-
tions from a site within muscle cells rather than at the plasma
membrane. Its extremely high (lownanomolar) afﬁnity for anunknown
protein insidemuscle cells led to a search for its binding site. In 1985, Dr.
Sidney Fleischer [131] prepared [3H]ryanodineand, in a series of focused
and ingenious experiments, used it in a functional test of the release of
Ca2+ from highly puriﬁed junctional terminal cisternae. Ruthenium red
blocked Ca2+ release, but, if the vesicles were pretreated with
nanomolar ryanodine, ruthenium red could no longer prevent Ca2+
release. Thus ryanodine was competing, with high afﬁnity, for a low
afﬁnity rutheniumred binding site on the Ca2+ release channel. In 1987,
Fleischer isolated the [3H]ryanodine-labeled Ca2+ release channel of the
skeletalmuscle sarcoplasmic reticulum, showed it to have a subunit size
greater than 400 kDa, and named it the ryanodine receptor (RyR) [132].
Shortly thereafter, the ryanodine receptor gene, RYR1, would be shown
to be the major genetic locus for MHS.
3.10. Discovery of luminal Ca2+ activation
Fleischer's studies of Ca2+ release from puriﬁed terminal cisternae
vesicles eventually led to the discovery of amechanism that is likely to
lie at the heart of the MH reaction (see later sections). Fleischer's
group showed that the ability of terminal cisternae vesicles to take up
increments of added Ca2+ was limited [132–136]. When the size of
the Ca2+ store reached a certain threshold, luminal Ca2+ triggered
rapid release of the Ca2+ store. This process has been termed store
overload-induced Ca2+ release (SOICR) [137,138]. Thus, in addition to
Endo's high afﬁnity cytosolic Ca2+ sensor site [139], there is a luminal,
low afﬁnity Ca2+ sensor site on the Ca2+ release channel [140] and
each of these sensors can trigger Ca2+ release.
3.11. Cloning of the ryanodine receptor gene
As the technology of molecular genetics advanced during the
1980s, it became possible to clone cDNAs encoding even huge
proteins. Cloning of the 15,000 bp encoding the skeletal muscle
ryanodine receptor was accomplished almost simultaneously by
Dr. Shosaku Numa's group for the rabbit RyR [141] and by our
group for both rabbit and human RyR [142]. Shortly, thereafter, both
groups cloned the homologous rabbit cardiac RyR cDNA [143,144] so
that the protein isoform expressed in skeletal muscle was termed
RyR1, encoded by the RYR1 gene, and the protein isoform expressed in
cardiac muscle was termed RyR2, encoded by the RYR2 gene.
3.12. Linkage of MH to RYR1
Publication of the human RYR1 cDNA sequencemade it possible for
geneticists worldwide to answer the question, posed two decadesearlier, whether the RYR1 gene, encoding the Ca2+ release channel of
the skeletal muscle sarcoplasmic reticulum, is the MH locus in
humans and in pigs. Back to back papers from our lab [145] and
Tommie McCarthy's lab [146] in 1990 showed linkage of human MH
to RYR1 on human chromosome 19, in a region that was isologous
with the location of the HAL gene on pig chromosome 6 that had been
established earlier [147]. The next step was to ﬁnd MH-causal
mutations in both human and pig RYR1/HAL genes. Fujii et al. [148]
reported the mutation of Arg 615 to Cys in the porcine RYR1/HAL gene
and, in a follow up, established linkage of this mutation to MH in
British Landrace pigs [149] with an astonishing lod score of 102
(traditionally, a lod score of 4 establishes linkage).
The discovery of the R615C mutation in pigs is one of the most
successful applications of molecular genetics to an animal disease.
Breeder selection for large hams and lean muscle mass inadvertently
led to selection for the MH gene, possibly ﬁrst in the Pietrain strain,
but later, through crossbreeding and further selection, it was
introduced into a variety of breeds. Haplotyping suggested that the
mutation was probably the same in all of the affected breeds, making
it likely that MH could be identiﬁed in the worldwide pig population
by testing for the presence of the R615 mutation [148]. Indeed, this
has proven to be the case, since no other pig MH mutation has been
detected in the past two decades and removal of the R615C mutation
frommuch of the world's breeding stock has dramatically reduced the
incidence of PSS and PSE in the pork industry. However, because the
mutation does add to muscle mass and because the Pietrain strain, in
particular, has adapted to its presence, themutation is still selected for
positively by some breeders.
In parallel studies, the corresponding mutation in a human MH
family (R614C) was soon identiﬁed [150] and, since then, some 300
MH-, CCD- and other congenital myopathy-associatedmutations have
been described in RYR1 (Fig. 1) [17,151,152]. Because of the large and
growing number of MH mutations in human RYR1, there is no simple
genetic test for MHS in humans as there is in pigs. Thus genetic testing
is still a laborious task that requires sorting through the sequence of
over 15,000 bp of RYR1 cDNA or 160,000 bp of RYR1 genomic DNA
[153]. Moreover, it is desirable that substitutions in the human RyR1
sequence be proven to be causal disease mutations, rather than
polymorphisms, by functional testing. To date, functional testing has
been carried out for only a fraction of known RyR1 mutations.
RYR1mutations have not been found in all MH families, leading to
the conclusion that other MH loci must exist. Indeed, genetic linkage
in some MH families have suggested an association of MH with
alternate chromosomal loci [154–158], but mutations that can be
considered causal have been found only in the CACNA1S gene (human
chromosome 1q) encoding the α-1 subunit (Cav1.1) of the skeletal
muscle voltage-gated Ca2+ channel (also referred to as the dihy-
dropyridine receptor or DHPR) [15,18–22]. In four out of the ﬁrst six
non-related MH cases with mutations in Cav1.1, the affected amino
acid residue was Arg1086, which was mutated either to His in three
heterozygous carriers [15,18,19] or to Ser in one homozygous carrier
[22]. Recently, two more Cav1.1 mutations – p.R174T [20] and p.
T1354S [21] – have been associated with MH. It is easy to rationalize
why mutations in Cav1.1 can cause MH, since each Cav1.1 subunit
interacts physically with a single RyR1 monomer in every other RyR1
tetramer, forming a complex that is integral to the EC coupling
machinery [159–162]. Functional analysis of the R1086H [163] and
T1354S [21] mutations revealed that their presence in the Cav1.1
subunit enhanced RyR1 sensitivity to activation by both endogenous
(voltage) and exogenous (caffeine) stimuli. Thus the effect of Cav1.1
mutations was essentially identical to that demonstrated for RyR1
MH mutations — enhanced sensitivity of the SR Ca2+ channel to
stimuli. It was suggested that the Cav1.1 subunit functions as a
negative allosteric modulator of RyR1 activation by these stimuli and
that mutations in Cav1.1 may disrupt this negative allosteric inﬂuence
[163].
Fig. 1. A plot of the accumulation of MH- and core myopathy-associated mutations in RyR1 against amino acids 1 to 5038 in the full-length human RyR1 protein. A total of 294 RyR1
amino acids in which at least 1 mutation has been documented are plotted cumulatively as blue dots relative to their position in the amino acid sequence. In cases where redundant
substitutions have occurred, they are assigned accumulation values equal to the redundancy at this site. In a second plot, using gray dots, we have assigned a value of only 1 to all
mutated amino acid sites, regardless of redundancy at the site. The two plots have the same overall shape, but the rate of accumulation is lower in the gray plot. The rates at which
RyR1 mutations are accumulated in relation to their location within the protein are presented graphically in the blue plot by the slopes (m) of linearized segments (red lines)
representing average values across each of the different segments of the plot. Six red lines subdivide the polypeptide chain into 6 major intervals designated HS1, CS1, HS2, CS2, HS3
and CS3, where HS stands for hot spot and CS for cooler spot, each with a different slope. The slope of each interval was determined as the ratio of the number of mutations within the
interval (N) divided by the length of the interval (Interval) in amino acid residues. HS1, HS2 and HS3 are regions with steep slopes, their “Start” and “End” coordinates being the
points of intersection of the red lines, indicated in the graph and in the inserted table. Within each of the HS sequences there are at least 2 subsequences, designated “a” and “b”, in
which the slopes differ from the average, some being much steeper. The intervals of these subsections are delineated in the inserted table by the ﬁrst and the last mutated amino acid
residue within the interval.
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have been shown to occur in mice with a knockout of the Casq1 gene
[164] encoding skeletal muscle calsequestrin, a low afﬁnity, high
capacity, Ca2+ binding/buffering protein located in the SR lumen
[165,166]. Later, we will return to the rationale for why the loss of
calsequestrin function might cause MH.
3.13. Linkage of CCD to RYR1
Because of the clinical association of some cases of MH with CCD,
the next step was to link CCD to mutations in the RYR1 gene. Again,
our lab [167] and Tommie McCarthy's lab [38] led the way in
demonstrating linkage in a number of CCD families. To date, no other
candidate gene for CCD has been proposed.While CCDmutations have
been found throughout the RYR1 gene, it is now clear that themajority
of CCD mutations are concentrated in the C-terminal end of RyR1
where 6 transmembrane (TM) sequences in each of the 4 subunits
assemble to form the ion pore region of the ion channel [168,169].
3.14. Distribution of MH and CCD mutations within RYR1
After the ﬁrst MHmutationwas found at amino acid 615, a number
of mutations were located near the N-terminus of RyR1. In a second
wave of discovery, MH and CCD mutations were found in a centralregion between amino acids 2100 and 2500 and, in a third wave,
mutations were found in the C-terminal region surrounding the
channel-forming region. These early studies suggested that there are
three mutation hot spots in RYR1, designated MHS1, MHS2 and MHS3
[157]. However, with time, some 300 mutations causing RyR1-related
disorders have been found throughout virtually the entire length of
RyR1 [17,151].
In Fig. 1, we have plotted the rate of accumulation of those amino
acid sites at which MH- or core myopathy-related mutations occur
(ordinate) against the 5038 amino acids that comprise human RyR1
(abscissa). At several sites, multiple substitutions associated with MH
or core myopathy have occurred (redundant mutations). To capture
this redundancy of causal mutations, we have assigned accumulation
values equal to the redundancy at each site in the plot created with
blue dots. In a second plot, using gray dots, we assigned a value of 1 to
all mutated amino acid sites, regardless of redundancy. The two plots
have the same overall shape, but a different accumulation rate.
Presentation of the accumulation of mutations in these ways
permits a redeﬁnition of the boundaries of the 3 hot spots. The three
mutation hotspots are now identiﬁed as HS1, HS2 and HS3 and
intervening regions are designated as CS1, CS2 and CS3 where HS
stands for Hot Spot, since the regions include mutations for both MH
and core myopathies, and CS stands for Cooler Spots, with a lower
density of cumulative mutations. The plots clearly show that, with a
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4338 and 4558, mutations are scattered throughout most of the RyR1
protein.
Different slopes in the red lines deﬁning the averaged rates of
accumulation of mutations in the blue plot indicate different regions
of the molecule in which mutations are accumulated with higher and
lower density. The HS1 region lies between amino acids 1–522
(m=0.094); the celebrated R615C mutation may not lie within hot
spot 1! HS2 is comprised of amino acids 2101–2548 (m=0.156) and
HS3 is comprised of amino acids 4631–4990 (m=0.228). Predicted
transmembrane (TM) sequence 1 (4557–4576) [168] is excluded
fromHS3, but TM sequences 2 (4637–4662), 3 (4776–4800), 4 (4803–
4825), 5 (4834–4854) and 6 (4911–4935) and the ion selectivity ﬁlter
(4896–4899) clearly lie within HS3. Within the HS regions there are
sub-regions in which the rate of accumulation of mutations is higher
than the average rate across the entire HS region. Region HS3b, with a
slope of 0.313 (~1 mutation in every 3 amino acids!), encompasses
amino acids 4793–4990, which excludes TM sequence 2 but includes
TM sequences 3, 4, 5 and 6 and the ion-selectivity sequence lying at
the heart of the ion pore. HS2b, with a slope of 0.285 encompasses
amino acids 2336–2548.
Comparison of the blue and gray plots shows that they have the
same overall shape, but a different accumulation rate. The value of this
comparison lies in its deﬁnition of where redundancy occurs. Thus the
spacing between the blue and gray lines runs more or less parallel
throughout regions CS1 and CS2, but the width of the blue-gray
spacing is increased dramatically after HS1, more after HS2 and even
more after HS3, indicative of the fact that multiple mutations of the
same amino acid are more concentrated in the 3 HS regions than
elsewhere in the molecule.
A comparison of the full sequences of all known RyR isoforms
shows 3 regions of high sequence diversity. They have been
designated divergent regions 1, 2 and 3 (D1, D2 and D3) [170–172].
D1, consisting of amino acids 4254–4631, contains the mutant-free
interval (4338–4558) referred to above. The entire D1 region in
human RyR1 contains only 9 mutations, including that in position
4631; the human D2 region, amino acids 1342–1403, contains 3
mutations, including that in position 1342; and the human D3 region,
amino acids 1872–1923, contains 1mutation. Thus, the relative lack of
functional mutations in these regions is themirror image of the lack of
conservation of these RyR1 sequences.
Dr. Noriaki Ikemoto and his colleagues have provided a possible
explanation for mutation clustering in HS1 and HS2 by proposing that
interactions between the N-terminal and central domains of RyR1 are
involved in regulation of the Ca2+ release channel, with these
interacting domains forming a ‘domain switch’ [173,174]. According
to their hypothesis, in the resting or non-activated state, the N-
terminal and central domains make close contact at several sub-
domains (domain zipping). The conformational constraints imparted
by the “zipped” conﬁguration of these two domains stabilize and
maintain the closed state of the Ca2+ channel. Stimulation via EC
coupling or pharmacological agents weakens these critical inter-
domain contacts, resulting in a reduction of conformational con-
straints (domain unzipping), thereby lowering the energy barrier for
Ca2+ channel opening. Weakening of the inter-domain interactions
may also occur viamutations of critical residues within these regions.
The fact that mutations are spread across the entire length of RyR1
raises the question of how can so many mutations impinge on the
same function— here proposed to be spontaneous Ca2+ release? Two
points can be made: ﬁrst, RyR1 mutations are identiﬁed because they
all cause MH or core myopathies — they really do have an effect on
RyR1 function! Second, in our earlier studies of mutations in the Ca2+
pump, we were able to deﬁne mutations that had speciﬁc effects
[175–178]. For example, we identiﬁed all of the key residues in the TM
sequences that bind Ca2+ and, with others, identiﬁed the residues in
two cytosolic domains that bind ATP. However, in one group ofmutations, amino acids scattered throughout all domains of the
molecule all blocked a critical conformational transition between E1P
and E2P. We called these “conformational change” mutations [176].
When Dr. Chikashi Toyoshima determined the crystal structures of
nine conformational states of SERCA1 [179,180] it was apparent that
there were huge movements of all of the 3 cytosolic domains and
several of the 10 TM helices. The A domain rotated 110°, and some of
the TM helices moved in and out of the membrane (http://www.
nature.com/nature/journal/v432/n7015/extref/nature02981-s6.
mov). Evidence now emerging from low resolution structures of RyR1
[181], strongly suggests that when high resolution structures of
different conformations of RyR1 are obtained, we will see that long-
range conformational changes utilize most domains within the
molecule, thereby explaining how wide-spread mutations that affect
conformational changes can impingeon a single function: increasing the
probability of spontaneous Ca2+ release. Indeed, such long-range
conformational changes lie at the heart of the postulate that inter-
domain unzipping of RyR1 subunits is involved in the activation of Ca2+
release channels [174].
3.15. Functional analysis of MH and CCD mutant proteins
Cloning of full-length forms of RyR1 opened the door to functional
analysis of mutant proteins by expressing them in a non-homologous
cell system such as HEK-293 cells that do not express endogenous
RyR1. Following transfection, RyR1 mutants are expressed in the ER,
an organelle that functions like the SR to store Ca2+ and regulate Ca2+
signaling in non-muscle cells. Ca2+ release transients can be
measured readily in these cells using Fura2 to image cytosolic Ca2+.
Cell permeable agonists such as caffeine and halothane can then be
administered to create dose response curves for induced Ca2+ release.
The ﬁrst experiments, conducted by Dr. Jeifei Tong [182–184],
recapitulated andextendedwhat had alreadybeendemonstratedby the
addition of caffeine and halothane to intact skeletal muscle ﬁbers. The
RyR1proteins carryingMHmutationswere all activatedbybothcaffeine
and halothane at concentrations lower than those that stimulated Ca2+
release with normal channels — they were hypersensitive to these
agonists. It was also possible to measure resting cytosolic Ca2+
concentrations in the presence of expressed RyR1 proteins and, since
the amplitude of the maximal Ca2+ release response is proportional to
the size of the luminal Ca2+ store, it was possible to measure the size of
Ca2+ stores [184]. A correlation was found between elevated cytosolic
Ca2+ and a decrease in the level of the Ca2+ store. When this was
extended to CCD mutant forms of RyR1, the resting cytosolic Ca2+ was
evenmore elevated thanwithMHmutants and the sizeof theCa2+store
was correspondingly diminished [182–184]. All of these experiments,
carried out in amodel system, provided proof that: (1)MHmutant Ca2+
release channel are hypersensitive to both caffeine and halothane; and
(2) in the presence of caffeine or halothane, they can cause a dramatic
shift in cellular Ca2+ regulation by increasing resting cytosolic Ca2+ and
diminishing Ca2+ stores. The increase in cytosolic Ca2+ is consistent
with the ability of these channels to promote contracture inmuscle cells
and the decrease in luminal Ca2+ is consistent with the idea, to be
developed in a later section, that MH arises frommutant channels that,
in the presence of halothane, have a lowered threshold for activation by
luminal Ca2+.
3.16. The discovery of “EC-uncoupled” CCD RyR1 mutants
In early studies, whenMH and CCDmutants had been located only in
cytosolic domains of RyR1, amutation lying in the center of the proposed
RyR1 selectivity ﬁlter (Ile4898 to Thr) [169,185] and causing a severe
formof CCD [183]was in uncharted territory. Studies of this RyR1mutant
in HEK-293 cells showed that the mutant channel exhibited little or no
caffeine-induced Ca2+ release [183]. This was consistent with either a
loss of Ca2+ release channel function or extreme depletion of the Ca2+
Fig. 2. Age-dependent accumulation of lesions within the skeletal muscle ﬁbers of
I4895T/+ mice.
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showed that cytosolic Ca2+was high, thus favoring a very leaky channel,
but this conclusion turned out to be wrong. Dr. Robert Dirksen had
developed a more physiological system for measuring Ca2+ release by
transfecting myotubes from dyspedic (Ryr1-null) mice with rabbit RYR1
mutant cDNAs, thereby reconstitutingECcoupling in thesemyotubes.His
studies showed that the I4898T mutant was nonfunctional with respect
to orthograde Ca2+ release, but retained the retrograde function of
stimulating Ca2+ entry through normal Cav1.1 [186,187]. These ﬁndings
have been conﬁrmed in functional studies on skeletal myotubes from an
I4895T mutant knockin mouse line [188].
These data on functional effects of CCD mutations presented a
paradox, since CCD and the formation of cores could be caused by two
types of mutants, those that were excessively active, elevating cytosolic
Ca2+ levels, and those that had diminished capacity for Ca2+ release and
did not elevate cytosolic Ca2+ levels [189–191]. In later sections, wewill
describe ﬁndings with the I4898T and Y522Smouse lines that will help
to explain how core lesions form and how they might be produced by
functionally different RyR1 mutations.
3.17. Generation of MH and CCD mouse lines
With a growing number of MH and CCD-associated RyR1
mutations, the need arose for the generation and comparative study
of animal models carrying different mutations. Recently 3 mouse lines
carrying knockin Ryr1mutations have been generated. A line carrying
the Ryr1R165C/+ mutation was developed by Dr. Paul Allen [192] and a
line carrying the Ryr1Y524S/+ mutations was developed by Dr. Susan
Hamilton [193]. These mutations are analogous to the heterozygous
human mutations RYR1R163C/+ and RYR1Y522S/+, which have been
described as being causal of MH [17]. In vitro and in vivo functional
studies of these mutations showed that both mutations render the
RyR1 channel highly sensitive to activation and lead to the elevation
of cytosolic Ca2+ levels. The third knockin line carries the EC-
uncoupling mutation, Ryr1I4895T/+ [177], analogous to the human
mutation, RYR1I4898T/+, one of themost frequent and highly penetrant
CCDmutations in humans [17,183,194]. It causes a severe form of CCD
with muscle weakness, but no apparent susceptibility to MH.
R163C has been found in more than 20 MH cases worldwide
[17,195–197]. In different MH families, the mutation shows a variable
clinical phenotype, manifesting as either MH only, as MHwith cores, or
as MH/CCD. Y522S has been found in twoMH families [38,198]. In both
families there were no clinical signs of muscle weakness. In the family
described by Quane et al. [38], two MHS family members had cores in
their skeletal muscle biopsies. In this case, Y522S was presented as an
MH mutation “with associated central cores” [38]. This was one of the
earliest attempts to discriminate between MH mutations presenting
with cores, but without muscle weakness, and MH/CCD mutations,
presenting with both cores and muscle weakness.
Heterozygous mice of both R163C (RC/+) and Y522S (YS/+) lines
develop fulminantMHepisodeswhen exposed to volatile anesthetics or
following short-term heat exposure [192,193]. Studies of these mouse
lines have permitted the acquisition of detailed insight into the etiology
ofMH inducedbyN-terminal leakyMH-causativeRyR1mutations [199–
202]. TheY522S linehas also served as a valuable tool for the elucidation
of core formation caused by an MH-associated RyR1 mutation [203].
Heterozygous mice of the I4895T (IT/+) line [204], carrying an
uncoupling C-terminal RyR1 mutation, exhibit a slowly progressive
myopathy with skeletal muscle weakness and age-dependent
formation of cores in their skeletal muscle, strikingly similar to the
pathology of RyR1-related core myopathies [29]. The IT/+ mouse line
holds great promise for investigation of the etiology and pathogenesis
of not only CCD, but also of the entire group of congenital muscle
weakness disorders, including multiminicore disease and nemaline
rod myopathy, since progressive formation of minicores, cores and
rods has been found in the skeletal muscle of I4895T mice [204].3.18. Insights into the mechanism of core formation in CCD and MH
mouse models
Examination of skeletal muscle samples from IT/+ mice [204] has
provided insights into the structural changes leading to core formation
that are caused by an EC-uncoupled CCD mutation (Fig. 2). The earliest
signs of ultrastructural abnormalities, in 6-week-old mice, consist of
irregularities of myoﬁbrillar organization, focal myoﬁbrillar thinning,
misalignment, and intermingling. This pattern suggests that local
abnormalities in myoﬁbrillogenesis occur sporadically. Analyses of
muscle samples from older mice revealed that these early structural
abnormalities undergo a transition from small, compacted areas
resembling minicores in younger animals to more extensive cores in
mice 6 months of age. By 12–18 months, nemaline rods are observed in
extended cores. Mitochondria are progressively displaced from the
center of the cores andaccumulate at the coreperiphery,while retaining
their normal non-swollen structure.
There is suggestive evidence for a similar age-dependent transition
in myoﬁber lesions in the skeletal muscles of CCD patients. In a few
CCD cases where repetitive skeletal muscle sampling was possible, no
abnormalities or only minicores were found in muscle biopsies from
younger patients, whereas cores were observed in muscle biopsies
taken at a later age [205,206] or in muscle biopsies of affected parents
[207–209]. Nemaline rods have also been detected in some CCD cases
[47,48,205,210].
Accordingly, it had been proposed that there is a common origin
for minicore, core, and rod lesions [205,210], but it had not been
possible to determine whether CCD cases with a mixed presentation
of lesions represent a typical course of disease progression or reveal
individual variability of the disease manifestation. The fact that IT/+
mice, express a full spectrum of minicores, cores and rods, in an age-
dependent progression, provides independent recent evidence sup-
porting the earlier proposals that these structural abnormalities
represent consecutive stages of skeletal muscle disease progression.
The relevance of the progressive pathological changes observed in
the I48985T mouse model to the disease progression in human CCD
cases has been demonstrated in a recent study in which rods were
found in the skeletal muscle samples of infant twins affected by an
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mutation of Ile4898 to Thr [194]. Taken together, these data from the
I48985T CCD mouse model and I4898T human carriers show that
structural abnormalities, conventionally attributed to distinct con-
genital myopathies and classiﬁed as MmD, CCD, and myopathy with
rods, do have a common etiology and pathogenesis [205,210].
Age-dependent structural abnormalities have also been found in
muscle ﬁbers from the YS/+ mouse model carrying a knockin of the
heterozygous leaky channel mutation, Y522S [199,203]. YS/+ mice
develop localized regions of mitochondrial and sarcotubular disrup-
tion as early as 2 months of age. In these focal regions of disruption,
mitochondria are swollen, presenting a more translucent matrix, and
exhibit signiﬁcant cristae remodelling. At this early stage, changes in
organelle structure are not accompanied by myoﬁbrillar contracture,
suggesting that they do not result from focally elevated Ca2+.
However, contracture and mitochondrial swelling resulting from
spontaneous Ca2+ release might follow different time courses so that
they would not have to appear together in the same ﬁxed section. A
contracture might be reversible and disappear in a very short time
frame, whereas the irreversibly swollen corpse of a mitochondrion,
disrupted during an earlier episode of spontaneous Ca2+ release,
might linger for a much longer period as the only remaining evidence
of that earlier episode. Between 3 and 12 months, the regions
exhibiting contracted myoﬁbrils that lack SR and mitochondria,
become prevalent and increase in area. By 12 months, these regions
encompass a larger area, they lack contractile elements, SR, and
mitochondria and they resemble unstructured cores in human
skeletal muscle biopsies [199,203].
The disruption of about 9% of mitochondria in young YS/+ mice
raises the question of how this structural feature relates to long-term
core formation. There are at least two possibilities; one is that
disruption of mitochondria, with its attendant potential for triggering
apoptosis, leads to the destruction and replacement of individual
muscle ﬁbers. To date, there is no evidence that this occurs. The other
is that these focal areas develop repeatedly, but do not progress
further and may even be reversible, so that damage to the myoﬁber is
surmountable. At some point, however, the damage becomes
irreversible so that the contraction cores progress to the larger
unstructured cores, as documented in older YS/+mice. Overall, these
studies of the ultrastructure of CCD and MH mouse models suggest
that EC-uncoupled IT/+ mutations and leaky YS/+ mutations result
in two distinct, progressive pathologies.
3.19. Characteristics of RyR2 mutations in CPVT
To date, only two genes have been deﬁnitively associated with MH
in humans: RYR1 and CACNA1S [158], but Casq1-null mice, developed
by Dr. Feliciano Protasi, have been shown to respond to halothane
with a typical MH response that is reversed by dantrolene [164,211].
This ﬁnding highlights the analogy between MH and CPVT, an
arrhythmogenic cardiac disorder caused by mutations in both RYR2
and CASQ2 genes, the isoforms expressed in the heart [137,212–216]
and raises the point that similarities between MH and CPVT can help
us to understand the underlying causes of these two diseases.
It is generally accepted that CPVT arrhythmias result from repetitive,
premature activationof RyR2, inotherwords, spontaneousCa2+release.
As described above, RyRs are activated by the elevation of luminal Ca2+
beyond a threshold at which SOICR is triggered [133,214,217–219]. We
have also discussed above howRyR function can bemeasured following
its expression in HEK-293 cells. In a remarkable series of experiments,
Dr. Wayne Chen's group adapted this system to measure the effect of
luminal Ca2+ on spontaneous Ca2+ release by wt RyR2 expressed in
HEK-293 cells [127,137,138,220,221]. They elevated luminal Ca2+ by
incremental elevation of extracellular Ca2+, which, in turn, elevates
cytosolic Ca2+ through plasma membrane leaks and then elevates the
luminal Ca2+ store through the action of sarco(endo)plasmic reticulumCa2+ ATPase (SERCA) pumps. They found that the percentage of cells in
which spontaneous oscillations of Ca2+ release and reuptake occur was
dramatically increased as extracellular Ca2+ was elevated incremental-
ly. At each incremental stage of elevation of extracellular Ca2+, it was
possible to measure the size of the luminal Ca2+ store. It doubled in
size, but reached amaximumwithabout the same incrementof external
Ca2+ that maximally activated spontaneous Ca2+ oscillations. Thus
there was a clear relationship between the elevation of luminal Ca2+
and the frequency of Ca2+ oscillations. As a further twist, the addition of
0.3 mMcaffeine,whichwas too low to activate the Ca2+ release channel
by itself, increased the frequency of Ca2+ oscillations dramatically.
Theseobservations conﬁrm,ﬁrst, thatwtRyR2has an intrinsic threshold
at which luminal Ca2+ can activate spontaneous Ca2+ release, and
second, that caffeine has the ability to lower the threshold at which
luminal Ca2+ can activate spontaneous Ca2+ release in cells transfected
with wt RyR2.
The next step was to measure the effect of elevating luminal Ca2+
on the spontaneous oscillations of CPVTmutations. RyR2 CPVTmutant
channels, expressed in HEK-293 cells, were activated by much lower
luminal Ca2+ levels than wt [137,138]. In fact, the level of activation
was equivalent to that seen in wt cells supplemented with 0.3 mM
caffeine. Critically, the size of the Ca2+ store for all CPVT mutants
studied was decreased as the frequency of Ca2+ oscillations was
increased. This implies that the CPVT mutation had lowered the
intrinsic threshold at which luminal Ca2+ can activate spontaneous
Ca2+ release. When single channel activities of RyR2 CPVT mutants
were measured in planar lipid bilayers with 45 nM cytoplasmic Ca2+,
incremental elevation of luminal Ca2+ from 0 to 1000 μM increased
the probability of opening (Po) to 0.3–0.4 for CPVT mutant RyR2s vs.
0.02 for wt RyR2. These results demonstrate that RyR2 CPVT mutant
channels, in isolation from other SR proteins, manifest a lower SOICR
threshold than wt RyR2, as illustrated in Fig. 3.3.20. Characteristics of RyR1 mutants in MH
What happens when an experiment analogous to that done with
RyR2 CPVT is carried out with MHmutations in RyR1? In a comparable
study, spontaneous Ca2+ release was studied for RyR1 R615C MH
mutantCa2+ release channels expressed inHEK-293 cells [127,220]. The
ﬁndingswere consistentwith the ﬁndings for RyR2 CPVTmutations.Wt
RyR1, expressed in HEK-293 cells, showed an increased rate of
spontaneous Ca2+ release as extracellular Ca2+ was elevated above
physiological levels in the presence of 0.7 mM halothane, a concentra-
tionofhalothane thatdoesnot stimulate spontaneousCa2+ release from
wt RyR1 in the presence of physiological levels of extracellular Ca2+. A
combination of elevated luminal Ca2+ and halothane increased
spontaneous Ca2+ release in both wt and MH mutant RyR1, but the
rate and frequency of spontaneous Ca2+ release was increased 20 fold
by 0.7 mMhalothane in MHmutant RyR1 [127]. In another experiment
in which the transfected R615C RyR1 MHmutant channel was induced
to undergo rapid spontaneous Ca2+ oscillations in the presence of
elevated Ca2+ and 2 mM caffeine, the addition of 100 nM dantrolene
blockedCa2+oscillations reversibly, apparently by suppressing SOICR in
these transfected HEK-293 cells. These results demonstrate that RyR1
MH mutations lower the threshold for luminal Ca2+ activation, that
volatile anesthetics and caffeine further lower the SOICR threshold, and
that dantrolene suppresses SOICR, as illustrated in Fig. 3.
The conclusions from these recent studies are fully in line with
conclusions reached in earlier studies performed with samples from
MH pigs. In a series of experiments, Nelson et al. [219,222,223]
showed that the MH defect in pig muscle lies in Ca2+ loading-
dependent activation of Ca2+ release from the SR. Although he called
the process Ca2+-induced Ca2+ release, it is clear that he was actually
referring to what is now termed store overload-induced Ca2+ release,
or SOICR.
Fig. 3. Amodel unifying the etiology of CPVT and MH arising frommutations in RYR or CASQ genes. The different thresholds for SOICR and the free SR luminal Ca2+ levels in CPVT or
MH, associated with mutations in RYR (A) or CASQ genes (B), are illustrated in the resting state (middle panels) and stimulated states (left and right panels). The normal SOICR
threshold is depicted as a dashed red bar. The SOICR threshold, that is lowered as a consequence of RyR mutations, is depicted as a solid red bar. The SOICR threshold that is lowered
by drugs (halothane or caffeine) is depicted as a solid yellow bar in the left panels. The SR free luminal Ca2+ level is represented as a blue area. The pink lozenges within the blue areas
represent Ca2+–Casq complexes, which are reduced as a result of point or truncationmutants (as depicted) or abolished as a result of null mutations (not depicted). The yellow areas
above the blue areas in the right panels represent an elevation, even if only transient, in the free Ca2+ levels that we propose will occur when SERCA activity is enhanced by
catecholamines. When the SOICR threshold is lowered below the SR free luminal Ca2+ level (left panels), or when the SR free luminal Ca2+ level surpasses, even transiently, the
normal SOICR threshold (right panels), SOICR occurs, leading to a spillover of SR Ca2+ that can trigger spontaneous Ca2+ release, cardiac arrhythmias or skeletal muscle contracture
(reprinted from [140]).
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In developing the argument that MH and CPVT share a common
feature – spontaneous Ca2+ oscillations triggered by SOICR – studies
of the effect of calsequestrin deﬁciency play a prominent role.
Calsequestrin increases the total SR luminal Ca2+ content through
its highly cooperative, high capacity, low afﬁnity Ca2+ binding that is
realized through the formation of Ca2+–Casq ﬁlaments that are built
through front-to-front and back-to-back polymerization, accom-
plished through arm exchange and domain swapping [165,224]. As
folding progresses, cooperative interactions bring acidic surface
residues together, literally creating new Ca2+ binding sites. Thus
Casq acts as a buffer against abrupt elevation of the free Ca2+ levels in
the SR lumen as Ca2+ is pumped inwards by the action of SERCA
pumps. CPVT mutations such as R33Q affect arm exchange and
domain swapping that are critical to proper folding, whereas other
mutations such as LI67H affect the folding of the hydrophobic core; in
either case, highly cooperative, high capacity Ca2+ binding is
disrupted [224].
The Ca2+–Casq ﬁlaments are connected to the luminal side of RyR
through triadin (Trd), a TM protein that binds to RyR1 through
intramembrane interactions and to ﬁlamentous Casq through luminal
interactions [225,226]. This arrangement of proteins situates Ca2+–
calsequestrin as a ﬁlamentous “wire” that can conduct Ca2+ directly
into the RyR pore [165,166,227–229]. Ablation of Casq bymutations in
CASQ1 or 2will reduce the total Ca2+ binding and buffering capacity of
the lumen by the amount that can be ascribed to Casq. Complete
ablation of Casq occurs in Casq-null mice, but point or truncation
mutations in Casq that affect key residues involved in arm exchange
and domain swapping or hydrophobic core stability can disrupt the
ability of mutant Casq to polymerize front-to-front and back-to-back,thereby abolishing cooperative, high capacity Ca2+ binding [224,230].
In the absence of Casq or in the presence of Casq with impaired
polymerization [230], and especially in a state where SERCA is fully
activated by adrenergic stimulation, diminished luminal Ca2+
buffering will permit luminal Ca2+ concentrations to overshoot the
normal threshold of wt RyR for SOICR, causing either an arrhythmia or
an MH episode, as illustrated in Fig. 3.
While it is generally agreed that the spontaneous release of SR Ca2+
is the primary process associated with the development of MH, there is
controversy about whether spontaneous Ca2+ release is a property
intrinsic toRyR orwhether Casq linked to RyR through interactionswith
Trd is involved in triggering spontaneous Ca2+ release. In another
publication [140], we have listed the reasons why we do not think that
Casq is a direct regulator of RyR.
4. A proposal that SOICR is the common triggering mechanism for
CPVT and MH episodes arising from mutations in RYR and
CASQ genes
As a summary of the observations on MH and CPVT discussed to
this point, CPVT and MHS individuals do not display abnormalities in
muscle structure or function at rest. Both result from abnormal,
repetitive Ca2+ cycling, characterized by spontaneous Ca2+ release
and reuptake. An arrhythmogenic CPVT episode is triggered in
response to physical or emotional stress, whereas a fulminant MH
episode, characterized by skeletal muscle contracture, hypermetab-
olism and fever is triggered in response to volatile anesthetics, stress
or elevated temperature. Causal RYR mutations are dominant,
reﬂecting the dominant impact of the mutations on channel function,
whereas causal CASQmutations are recessive, reﬂecting the fact that it
is the dramatic reduction in cooperative, high capacity, low afﬁnity
Fig. 4. RyR1 tetramer grid showing all sixteen combinations of subunit assembly from
equal numbers of wt (green) and mutant (red) subunits and the resulting relative
function of the different channels. Superimposed on the grid are black dots
representing DHPR tetramers. The relative amplitude of Ca2+ release from each
tetramer is depicted by a yellow “puff”, approximating the relative results of single
channel recordings for heterozygous I4898T mutations in which 3 groups were
observed: Dark yellow puff; normal (100%) Ca2+ conductance (5 channels out of 20);
Light yellow puff; decreased (88%) Ca2+ conductance (6 out of 20); and no puff,
corresponding to 0 Ca2+ conductance (9 out of 20). The presence of 3 functionally
different groups of RyR1 tetramers in a roughly equal ratio is consistent with the view
that the group with normal channel activity includes not only wt homotetramers, but
also tetramers with 3 wt and 1 mutant subunits, for a cumulative fraction of 5/16; that
the group of channels with decreased Ca2+ channel activity is formed by tetramers with
2 mutant and 2 wt subunits, for a cumulative fraction of 6/16; and that the group of
inactive channels includes not only mutant homotetramers, but also tetramers with 3
mutant and 1 wt subunits, for a cumulative fraction of 5/16 [236].
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or arrhythmia.
We believe that a common mechanism underlies the triggering of
arrhythmias caused by RYR2 or CASQ2 CPVTmutations and themuscle
contracture caused by RYR1 or CASQ1 MH mutations (Fig. 3). We
propose that, in all cases, the free SR luminal Ca2+ level repetitively
exceeds the threshold for SOICR, leading to spontaneous Ca2+ release.
In CPVT, RyR2 mutants have a lower than wt threshold for SOICR.
Under conditions of exercise or stress, when the β-adrenergic
pathway is stimulated, phospholamban (PLN) becomes phosphory-
lated by PKA. PLN is a critical regulator of cardiac contractility [231],
which suppresses Ca2+ uptake into the SR by reducing the apparent
afﬁnity of SERCA2a for Ca2+. When phosphorylated, the inhibitory
function of PLN is lost and SERCA becomes fully active, bringing about
a surge in Ca2+ entry into the lumen of the SR. This surge causes the
level of free Ca2+ to overshoot the SOICR threshold of mutant RyR2,
which has been lowered by the CPVT mutation. This sets up repetitive
oscillations consisting of an increased rate of Ca2+ entry into the SR,
together with an increased rate of spontaneous Ca2+ release that is
triggered by a much lower level of luminal Ca2+. Although the
amplitude of Ca2+ release is lowered in proportion to the lowered size
of the Ca2+ store, the general elevation of cytosolic Ca2+ is sufﬁcient
to increase the rate of Na+/Ca2+ exchange, which depolarizes the
membrane sufﬁciently to set up delayed after depolarizations (DADs)
that manifest as a triggered arrhythmia. Casq2 mutants, which fail to
perform their function as luminal Ca2+ binding and buffering
proteins, will no longer be able to provide the buffering capacity
required to prevent free luminal Ca2+ levels from overshooting the
normal RyR2 SOICR threshold when SERCA-dependent Ca2+ uptake is
increased. In either case, repetitive SOICR manifests as triggered
arrhythmia.
In MH, RyR1 mutants have a lowered threshold for SOICR. In the
presence of halothane, which further lowers its mutation-lowered
SOICR threshold, RyR1 will be triggered to open when the free SR
luminal Ca2+ level overshoots its lowered SOICR threshold. Casq1
mutants have a reduced luminal Ca2+ binding and buffering capacity,
allowing free luminal Ca2+ levels to overshoot the halothane-lowered
SOICR threshold of wt RyR1. In either case, a cycle is initiated in which
SERCA pumps only partially reﬁll the luminal Ca2+ store before SOICR
is triggered. Repetitive SOICR elevates cytosolic Ca2+ to provide
signals for skeletal muscle contracture and hypermetabolism, where-
as fever arises from enhanced ATP hydrolysis by SERCA and myosin
ATPase [140].
While we propose that SOICR is the underlying cause of these
disorders, the overall process of spontaneous Ca2+ release almost
certainly incorporates elements of other mechanisms that have been
described: inter-domain unzipping of RyR subunits, changes in RyR
redox status, increased rate of Ca2+ entry into the SR lumen following
adrenergic stimulation resulting from emotional or physical stress,
changes in RyR phosphorylation status, and elevated enzymatic
function arising from elevated temperatures.
5. A proposal that non-uniformity of Ca2+ Release Unit (CRU)
function underlies phenotypic variability, variable penetrance and
core formation in CCD and RyR1-related congenital myopathies
As an introduction to this ﬁnal section, we restate that RYR1 is the
only known causal gene for CCD and related core myopathies. RyR1 is
a tetramer of 2.3 MDa, assembled from identical ~565 kDa subunits. In
the junctional terminal cisternae of the SR, tetrameric RyR1molecules
form ordered 2D arrays, in which each of the four subunits in every
other RyR1 tetramer is physically coupled to a DHPR complex located
in the transverse tubular membrane [159–162], and each RyR1
tetramer is physically coupled to 4 other RyR1 tetramers through
interactions centered around subdomain 6 [128,129]. The precise
organization of these two systems, referred to as Ca2+ release Units orCRUs, is a critical feature of skeletal muscle EC coupling, since
cooperative functional interaction within this unit accounts for the
temporal and spatial uniformity of Ca2+ release that underlies the
uniformity of skeletal muscle contraction.
The abrupt transition from sarcomeric register to lack of register
was one of the most prominent ultrastructural abnormalities in CCD
muscle in the earliest publications on human CCD [35,69]. A plausible
explanation for the lack of sarcomeric register is a lack of uniformity of
Ca2+ release, arising from a lack of functional uniformity among the
CRUs that regulate the contraction of those sarcomeres that lie within
the CRU regulatory domain. An important question is how could non-
uniformity of Ca2+ release arise from a heterozygous Ca2+ release
channel? The answer may lie in the way in which the tetrameric
channel is assembled.
CCD is typically associated with heterozygous missense RyR1
mutations, implying that expression of both wt and mutant RyR1
subunits occurs within the skeletal muscle. Random combination of
subunits into RyR1 tetramers would produce six possible variants:
homotetrameric wild type channels of normal activity; homotetra-
meric mutant channels of compromised or null activity; and
heterotetrameric channels of intermediate activity arising from four
possible tetrameric arrangements of wt:mutant subunits (3:1; 1:3;
2:2, side by side; 2:2, diagonally apposed). The 16 possible arrange-
ments of subunits into tetramers are illustrated in Fig. 4. The level of
expression of mutant subunits may vary, depending on the nature of
each individual mutation. However, if we assume that the expression
of wt and mutant subunits is similar, then 1/16 of all RyR1 tetramers
would be fully active wt homotetramers; 1/16 would be mutant
homotetramers of maximally compromised activity; and 14/16 would
exhibit an intermediate level of functional competence, which would
likely be unique for each mutation [231,232]. The random association
of two different subunits within each tetramer, followed by the
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CRU, would now set the stage for non-uniformity of Ca2+ release
among CRUs. This would then lead to non-uniformity of contraction
among sarcomeric domains, each of which could be regulated by a
functionally different CRU. The effects of non uniformity of Ca2+
release could be ampliﬁed beyond the level of the sarcomere; to the
myoﬁbril the myoﬁber and the muscle fasciculus. It could also alter
other Ca2+-dependent processes within the skeletal muscle, such as
energy production, myoﬁbrillar structure and maintenance, thereby
contributing signiﬁcantly to the phenotypic variability that charac-
terizes RyR1-related myopathies.
There is ample historical evidence for non-uniformity of function
for RyR1 tetramers in studies of heterozygous MH and CCD mutant
carriers [232–235]. Dr. TomNelson [232] detected 2 groups of SR Ca2+
release channels in skeletal muscle biopsies from 4 MH patients with
unidentiﬁed mutations. Among 13 single channels recorded, 7
exhibited the functional activity of mutant channels, while 6 exhibited
normal activity, corresponding to wt channels. Dr. Nirah Shomer [233]
measured the function of isolated single channels from heterozygous
R614C MH pig muscle, and classiﬁed them into 3 groups: wild-type
homotetramer; mutant homotetramer; and mutant heterotetramer
[234]. Dr. Gerhard Meissner [235] measured the single channel
function of several transiently expressed CCD andMmDRyR1mutants
and conﬁrmed that homotetrameric wild-type and mutant RyR1
channel functions were present, together with heterotetrameric
channels of varying functional activity. For some RyR1 mutations,
the presence of only one mutant subunit was sufﬁcient to affect the
properties of the tetramer, while for other mutations, more than one
subunit was required [235]. In total, these studies show that
functional variability is an intrinsic feature of the heterozygous
expression of Ca2+ release channels in RyR1-related congenital
myopathies and MH.
Studies of the lack of uniformity of Ca2+ release channel function
in MH or CCD mutant RyRs have now been carried forward to the
investigation of mouse models, in particular, the IT/+ model of CCD.
The homozygous expression of the Ryr1I4895T EC-uncoupled CCD
mutation in a KI mouse line was neonatally lethal. However, the
homozygous (IT/IT) mutant RyR1 subunits were expressed in normal
amounts, assembled into tetramers and targeted correctly to the
junctional SR, where they formed ordered arrays in precise juxtapo-
sition with DHPR complexes [188]. IT/IT RyR1 was devoid of
orthograde Ca2+ release channel activity, but retained the ability to
support the retrograde entry of Ca2+ through its interaction with
DHPR. Thus the loss of orthograde Ca2+ release function did not alter
either the structural integrity of the RyR1 protein or the supramolec-
ular organization of the CRU.
Heterozygous Ryr1I4895T/+ (IT/+) mice survived the neonatal
period. The earliest morphological abnormality seen in skeletal
muscle from the IT/+ mouse line was a lack of uniformity of skeletal
muscle contraction in very youngmice (Fig. 2, upper panel) [204]. The
mice then developed progressive core myopathy over the next 8 to18
months [204]. The phenotype was exhibited on a stable genetic
background, thus minimizing genetic variability. Moreover, RT-PCR
analyses revealed equimolar levels of expression of wt and mutant
Ryr1 transcripts, while western blotting experiments showed that
total RyR1 protein content was unchanged by themutation. In spite of
these facts, there was variation in disease penetrance.
In a search for possible variant functions in heterozygous I4898T
RyR1 channels [236], measurements of single channel activity
revealed the co-existence of 3 functionally different groups of RyR1
tetramers: those with normal Ca2+ conductance (5 channels out of
20); those with a 12% decrease in Ca2+ conductance (6 out of 20); and
those with no Ca2+ conductance (9 out of 20). The presence of three
functional groups of RyR1 tetramers at a roughly equal ratio is
inconsistent with the view that only 1/16 of the RyR1 molecules,
containing only wt subunits, will be fully active; that 1/16 of the RyR1molecules, containing only mutant subunits, will be inactive; and that
14/16, containing varying ratios of wt and mutant subunits, will have
variable activities. It is, however, fully consistent with the assumption
that the group with normal channel activity includes not only wt
homotetramers, but also tetramers with 3 wt and 1 mutant subunits,
for a cumulative fraction of 5/16; that the group of inactive channels
includes not only mutant homotetramers, but also tetramers with 3
mutant and 1 wt subunits, for a cumulative fraction of 5/16; and
that the group of channels with 12% decreased Ca2+ channel activity
is formed by tetramers with 2 mutant and 2 wt subunits, for a
cumulative fraction of 6/16. This deduced distribution of functional
activity among various IT/+ tetramers is shown schematically in
Fig. 4. For the speciﬁc case of I4898T/wt expression, a dark yellow
“puff” of Ca2+ release illustrates 100% of full activity; a light yellow
puff represents 88% of full activity and the lack of a puff indicates
essentially 0 channel function for the different combinations of
subunits resulting from heterozygous expression of this speciﬁc
mutation.
These data support the view that there is functional heterogeneity
among I4898T RyR1 tetramers. Indeed, the incorporation of IT mutant
subunits into Ca2+ release channel tetramers results in a dominant-
negative suppression of Ca2+ conductance that reduces the overall
rate and magnitude of Ca2+ release, by 36% [236]. We propose a
further layer of complexity: the random distribution of channels
within each CRU harbors the potential to lead to both non-uniformity
of Ca2+ release among CRUs and to non-uniformity of contraction
among individual sarcomeres regulated by these individual CRUs. We
have proposed that the resulting non-uniformity of sarcomeric
contraction is the underlying cause of the variable disease phenotype
in heterozygous IT/+ mice [204].
Our EM studies captured the ultrastructural consequences of the
heterogeneity of contraction that exists within IT/+ myoﬁbers [204].
The discordant contraction between adjacent myoﬁbers is ﬁrst seen as
the disruption of sarcomeric register. Such discordance would create
physical stresses within myoﬁbers that would lead to tearing and
shearing between myoﬁbrils and to displacement of mitochondria and
the sarcotubular and system that would, over time, cause physical and
functional damage to Ca2+ regulatory, energetic and contractile
systems As these processes progress, small foci of damage would
coalesce and manifest as minicores, cores and rods that would
compromise muscle function and force, further diminishing muscle
strength. It is well established, in both human CCD patients and in IT/+
mice, that cores are not the primary cause of muscle weakness, since
cores often form late in life, whereas muscle weakness usually
manifests perinatally or during the ﬁrst years of life [204–209].
However, cores may represent an aggravating factor and further
compromise muscle strength in a progressive manner. Most impor-
tantly, the heterogeneity of Ca2+ release and contractile force would
occur, regardless of whether the heterozygous RyR1mutation acted by
rendering the channel hypersensitive to stimuli (MH and some CCD
mutations) or by interfering with Ca2+ conductance/gating/perme-
ation (the majority of CCD mutations).
On the basis of these observations and deductions, we propose the
unifying theory that the pathogenic mechanism leading to the
formation of structural abnormalities and to clinical variability in
MH, CCD and other RyR1-related muscle disorders is the differential
release of Ca2+ from functionally disparate, heterozygous CRUs [204].
6. Conclusions
Research over the past 50 years on MH, CCD and CPVT has
recorded steady progress in our understanding of their etiology and
pathology. As one result, therapeutic agents such as dantrolene for
MH and β-blockers for CPVT have been incorporated into medical
practice. Through genetic testing, many individuals in MH and CPVT
affected families can be identiﬁed and potentially fatal MH episodes or
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animal models for these diseases is well underway and analyses of
these models will continue to provide insights into molecular
processes leading to the various diseases. Such studies will also
contribute to our understanding of the fundamental mechanisms of
EC coupling and the principles of skeletal muscle contractility that
function in health and disease. Ultimately, mouse model lines will
offer the potential for testing therapeutic approaches that might help
combat these disorders and diseases.
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